Related references
Note: Only part of the references are listed.Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy
Yiyi Cao et al.
TUMORI JOURNAL (2021)
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study
Gilles R. Dagenais et al.
LANCET (2020)
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
Jhanelle E. Gray et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials
Dawei Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study.
Cristina Masini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer A Nonrandomized Controlled Trial
Salma K. Jabbour et al.
JAMA ONCOLOGY (2020)
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
Julijan Kabiljo et al.
CANCERS (2020)
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Michael A. Postow et al.
CLINICAL CANCER RESEARCH (2020)
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study
Steven F. Powell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179
Greg A. Durm et al.
CANCER (2020)
Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 PembroRad randomized trial
J. Bourhis et al.
ANNALS OF ONCOLOGY (2020)
Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
E. E. Cohen et al.
ANNALS OF ONCOLOGY (2020)
Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis
Congzhou M. Sha et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade
Xinrui Zhao et al.
CANCERS (2020)
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study
Chiara Pozzessere et al.
ERJ OPEN RESEARCH (2020)
Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma
L. Quero et al.
CANCER RADIOTHERAPIE (2019)
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
Sayuri Miyauchi et al.
CLINICAL CANCER RESEARCH (2019)
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Maria E. Rodriguez-Ruiz et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
Cecilia Roux et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The molecular machinery of regulated cell death
Daolin Tang et al.
CELL RESEARCH (2019)
Immunogenic cell death in cancer therapy: Present and emerging inducers
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial
Joshua M. Bauml et al.
JAMA ONCOLOGY (2019)
Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
Eric Deutsch et al.
LANCET ONCOLOGY (2019)
1457PDEfficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial
S Peters et al.
ANNALS OF ONCOLOGY (2019)
The Abscopal Effects of the Combination of Radiotherapy and GM-CSF for Patients with Metastatic Thoracic Cancers
M. Liu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4
Sergio A. Quezada et al.
CLINICAL CANCER RESEARCH (2019)
Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges
Hui Yang et al.
PRECISION CLINICAL MEDICINE (2019)
Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?
Mathieu Spaas et al.
FRONTIERS IN MEDICINE (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Lorenzo Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2018)
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Ariel E. Marciscano et al.
CLINICAL CANCER RESEARCH (2018)
A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors
Bhanu Prasad Venkatesulu et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases
Charlee Nardin et al.
MELANOMA RESEARCH (2018)
Safety of combining radiotherapy with immune-checkpoint inhibition
William L. Hwang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma
Qian Qin et al.
RADIATION RESEARCH (2018)
Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma
Tetsuya Komatsu et al.
JAPANESE JOURNAL OF RADIOLOGY (2018)
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
Carl DeSelm et al.
MOLECULAR THERAPY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer
S. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Chad Tang et al.
CLINICAL CANCER RESEARCH (2017)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy
William A. Stokes et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination
Amelie Aboudaram et al.
MELANOMA RESEARCH (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger?
Raffaella Marconi et al.
PLOS ONE (2017)
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Heath D. Skinner et al.
CLINICAL CANCER RESEARCH (2017)
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
K. A. Ahmed et al.
ANNALS OF ONCOLOGY (2016)
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses
Serena S. Kwek et al.
ONCOIMMUNOLOGY (2016)
Timing and Type of Immune Checkpoint Therapy Affect the Early Radiographic Response of Melanoma Brain Metastases to Stereotactic Radiosurgery
Jack M. Qian et al.
CANCER (2016)
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
Maria E. Rodriguez-Ruiz et al.
CANCER RESEARCH (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma
Susan M. Hiniker et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Michael B. Bernstein et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Modern Radiotherapy Concepts and the impact of Radiation on immune Activation
Lisa Deloch et al.
FRONTIERS IN ONCOLOGY (2016)
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
Kristina H. Young et al.
PLOS ONE (2016)
Immune Priming of the Tumor Microenvironment by Radiation
Wen Jiang et al.
TRENDS IN CANCER (2016)
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Michael Spiotto et al.
SCIENCE IMMUNOLOGY (2016)
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
Claire Vanpouille-Box et al.
CANCER RESEARCH (2015)
Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
Ana P. Kiess et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
Encouse B. Golden et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
PD-1 Restrains Radiotherapy-Induced Abscopal Effect
Sean S. Park et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
S. J. Dovedi et al.
ONCOIMMUNOLOGY (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Radiation and immunotherapy: a synergistic combination
Anusha Kalbasi et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia C. Formenti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Christopher A. Barker et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
Inge Verbrugge et al.
CANCER RESEARCH (2012)
Maximizing Tumor Immunity With Fractionated Radiation
Doerthe Schaue et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival Clinical article
Jonathan P. S. Knisely et al.
JOURNAL OF NEUROSURGERY (2012)
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2: Tumor and Immunological Responses
Steven K. Seung et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Radiation as an immunological adjuvant: current evidence on dose and fractionation
Sandra Demaria et al.
FRONTIERS IN ONCOLOGY (2012)
TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo
Fanny Bouquet et al.
CLINICAL CANCER RESEARCH (2011)
RADIATION ENHANCES REGULATORY T CELL REPRESENTATION
Evelyn L. Kachikwu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Isoform-specific activation of latent transforming growth factor β (LTGF-β) by reactive oxygen species
Michael E. Jobling et al.
RADIATION RESEARCH (2006)
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
AV Maker et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Share Paper
